Profiling galcanezumab in episodic migraine, cluster headache, and medication overuse headache.

IF 4.3 2区医学 Q2 CLINICAL NEUROLOGY

Expert Review of Neurotherapeutics Pub Date : 2026-07-01 Epub Date: 2026-05-25 DOI:10.1080/14737175.2026.2675009

Abimael González-Hernández, José D Ferrusca, Carlos M Villalón

{"title":"Profiling galcanezumab in episodic migraine, cluster headache, and medication overuse headache.","authors":"Abimael González-Hernández, José D Ferrusca, Carlos M Villalón","doi":"10.1080/14737175.2026.2675009","DOIUrl":null,"url":null,"abstract":"Introduction: The introduction of monoclonal antibodies (mAbs) targeting the calcitonin gene-related peptide (CGRP) pathway has revolutionized migraine treatment. In this regard, galcanezumab, a humanized immunoglobulin G4 (IgG4) that binds the CGRP molecule, has rapid onset of action, monthly dosing, and favorable pharmacokinetics.Areas covered: This review, which draws upon electronic databases such as PubMed, Web of Science, FDA, and EMA, provides a comprehensive summary of galcanezumab for migraine prophylaxis. It covers the drug's mechanism of action, its clinical efficacy in episodic migraine, and its potential benefits in episodic cluster headache and medication-overuse headache. It also provides an overall safety profile based on clinical trials and real-world studies.Expert opinion: Galcanezumab is a cornerstone preventive therapy with consistent efficacy, favorable tolerability, and convenient dosing. Key unmet needs include identifying biomarkers to predict responders, addressing access and cost barriers, optimizing evaluation windows for late-responders, and expanding the evidence base for special populations (pediatrics, pregnancy, and vascular comorbidities). Future studies should refine patient selection and explore complementary targets for non-responders.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"619-629"},"PeriodicalIF":4.3000,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Neurotherapeutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14737175.2026.2675009","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/5/25 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: The introduction of monoclonal antibodies (mAbs) targeting the calcitonin gene-related peptide (CGRP) pathway has revolutionized migraine treatment. In this regard, galcanezumab, a humanized immunoglobulin G4 (IgG4) that binds the CGRP molecule, has rapid onset of action, monthly dosing, and favorable pharmacokinetics.

Areas covered: This review, which draws upon electronic databases such as PubMed, Web of Science, FDA, and EMA, provides a comprehensive summary of galcanezumab for migraine prophylaxis. It covers the drug's mechanism of action, its clinical efficacy in episodic migraine, and its potential benefits in episodic cluster headache and medication-overuse headache. It also provides an overall safety profile based on clinical trials and real-world studies.

Expert opinion: Galcanezumab is a cornerstone preventive therapy with consistent efficacy, favorable tolerability, and convenient dosing. Key unmet needs include identifying biomarkers to predict responders, addressing access and cost barriers, optimizing evaluation windows for late-responders, and expanding the evidence base for special populations (pediatrics, pregnancy, and vascular comorbidities). Future studies should refine patient selection and explore complementary targets for non-responders.

查看原文本刊更多论文

galcanezumab在发作性偏头痛、丛集性头痛和药物滥用性头痛中的临床应用。

导语：针对降钙素基因相关肽（CGRP）途径的单克隆抗体（mab）的引入已经彻底改变了偏头痛的治疗。在这方面，galcanezumab是一种结合CGRP分子的人源化免疫球蛋白G4 (IgG4)，具有快速起效，每月给药和良好的药代动力学。涵盖领域：本综述利用PubMed、Web of Science、FDA和EMA等电子数据库，提供了galcanezumab用于偏头痛预防的综合总结。它涵盖了药物的作用机制，它在阵发性偏头痛中的临床疗效，以及它在阵发性丛集性头痛和药物过度使用头痛中的潜在益处。它还提供了基于临床试验和现实世界研究的总体安全性概况。专家意见：Galcanezumab是一种基础预防治疗，具有一致的疗效，良好的耐受性和方便的剂量。关键的未满足需求包括识别生物标志物来预测应答者，解决获取和成本障碍，优化迟到者的评估窗口，以及扩大特殊人群（儿科、妊娠和血管合并症）的证据基础。未来的研究应完善患者选择，并探索无反应的补充靶点。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Neurotherapeutics Medicine-Neurology (clinical)

CiteScore

7.00

自引率

2.30%

发文量

审稿时长

4-8 weeks

期刊介绍： Expert Review of Neurotherapeutics (ISSN 1473-7175) provides expert reviews on the use of drugs and medicines in clinical neurology and neuropsychiatry. Coverage includes disease management, new medicines and drugs in neurology, therapeutic indications, diagnostics, medical treatment guidelines and neurological diseases such as stroke, epilepsy, Alzheimer''s and Parkinson''s. Comprehensive coverage in each review is complemented by the unique Expert Review format and includes the following sections: Expert Opinion - a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results Article Highlights – an executive summary of the author’s most critical points